Skip to main content
SpringerLink
Log in

Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Doxorubicin-resistant metastatic breast cancer (MBC) is a very poor prognosis scenario, where only taxanes have shown activity, often at the expense of severe toxicity that compromises palliation. This study was undertaken to test the antitumor activity and tolerability of infusional 5-fluorouracil (5-FU) modulated with low-dose oral leucovorin (LV), in heavily pretreated patients with stringent criteria of primary resistance to doxorubicin, visceral involvement, and suboptimal performance status. Twenty-six patients with measurable MBC and primary resistance to anthracyclines received a weekly outpatient 48-hour infusion of high-dose 5-FU with low dose oral leucovorin. All patients were assessable for response and toxicity. Eight partial responses were seen (30% response rate) in soft tissue and visceral sites, with a median response duration of eight months (5 + to 12). 98% of the cycles were minimally toxic or non-toxic. Toxicities included mucositis, diarrhea, and plantar-palmar-syndrome. Our results suggest that this schedule of LV-modulated infusional 5-FU can produce a substantial number of long-lasting responses and meaningful palliation to this very poor prognosis population.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. O'Connell MJ: A phase III trial of 5-fluorouracil and leucovorin in the treatment of advanced colorectal cancer. A Mayo Clinic/North Central Cancer Treatment Group study. Cancer 63: 1026–1030, 1989

    Google Scholar 

  2. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ: Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 890–899, 1989

    Google Scholar 

  3. Loprinzi CL, Ingle JN, Schaid DJ, Buckner JC, Edmonson JH, Allegra CJ: 5-Fluorouracil plus leucovorin in women with metastatic breast cancer. Am J Clin Oncol 14: 30–32, 1991

    Google Scholar 

  4. Doroshow JH, Leong L, Margolin KA, Odujinrin O, Newman E: Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. J Clin Oncol 7: 439–444, 1989

    Google Scholar 

  5. Margolin KA, Doroshow JH, Akman SA, Leong LA, Morgan RJ, Somlo G, Raschko J, Pereira C, Yonemoto L, Ahn C: Effective initial therapy of advanced breast cancer with fluorouracil and high-dose continuous infusion calcium leucovorin. J Clin Oncol 10: 1278–1283, 1992

    Google Scholar 

  6. Lokich J, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 7: 425–432, 1989

    Google Scholar 

  7. Weinerman B, Shah A, Field A et al.: A randomized trial of continuous systemic infusion versus bolus therapy with 5-fluorouracil in metastatic measurable colorectal cancer. Proc Am Soc Clin Oncol 7: 425–432, 1990

    Google Scholar 

  8. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group Study. J Clin Oncol 13: 1303–1311, 1995

    Google Scholar 

  9. Huan S, Pazdur R, Singhakowinta A, Samal B, Vaitkevicius VK: Low-dose continuous infusion 5-fluorouracil. Cancer 63: 419–422, 1989

    Google Scholar 

  10. Jabboury K, Holmes FA, Hortobagyi G: 5′-fluorouracil rechallenge by protracted infusion in refractory breast cancer. Cancer 64: 793–797, 1989

    Google Scholar 

  11. Smith IE, Walsh G, Jones A, Prendiville J, Johnston S, Gusterson B, Ramage F, Robertshaw H, Sacks N, Ebbs S, et al.: High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 13: 424–429, 1995

    Google Scholar 

  12. Romanini A, Lin JT, Niedzwiecki D, Bunni M, Priest PG, Bertino JR: Role of folylpolyglutamates in biochemical modulation of fluoropyrimidines by leucovorin. Cancer Res 51: 789–793, 1991

    Google Scholar 

  13. Moran RG, Scanlon KL: Schedule dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51: 4618–4623, 1991

    Google Scholar 

  14. Leichman CG, Leichman L, Spears CP, Rosen PJ, Jeffers S, Groshen S: Phase II study of prolonged infusion 5-fluorouracil with weekly leucovorin in disseminated colorectal cancer. J Natl Cancer Inst 85: 41–44, 1993

    Google Scholar 

  15. Aranda E, Cervantes A, Dorta J, Blanco E, Fernández-Martos C, Cruz-Hernández JJ, Carrato A, González-Mancha R, García-Conde J, Díaz-Rubio E: A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. Cancer 76: 559–563, 1995

    Google Scholar 

  16. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207–214, 1981

    Google Scholar 

  17. Martín M, Díaz-Rubio E, Casado A, López JA, Rodríguez A, Ayala F, Nieto Y: FlexiFAC: A modified schedule for breast cancer. Proc Am Soc Clin Oncol 13: 107 (abstr. 229), 1994

    Google Scholar 

  18. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Bhandari A, Valero V, Buzdar AU: A unified definition of clinical anthracycline resistant breast cancer. Proc Am Soc Clin Oncol 16: 146a (abstr. 512), 1997

    Google Scholar 

  19. Wilke H, Klaassen U, Achterrath W, Losch M, Vanhocfer U, Hayungs J, Harstrick A, Stahl AM, Eberhardt W, Becher R, Seeber S: Phase I/II study with a weekly 24-hour infusion of 5-fluorouracil plus high-dose folinic acid (HD-FU/FA) in intensively pretreated patients with metastatic breast cancer. Ann Oncol 7: 55–58, 1996

    Google Scholar 

  20. Valero V, Holmes F, Walters R, Theriault RL, Esparza L, Fraschini G, Fonseca GA, Bellet RE, Buzdar AU, Hortobagyi GN: Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 13: 2886–2894, 1995

    Google Scholar 

  21. Ravdin P, Burris H III, Cook G, Eisenberg P, Kane M, Bierman WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879–2885, 1995

    Google Scholar 

  22. Wilson WH, Berg SL, Bryant G, Wittes RE, Bates S, Fojo A, Steinberg SM, Goldspiel BR, Herdt J, O'Shaughnessy J: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 12: 1621–1629, 1994

    Google Scholar 

  23. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P, Norton L: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 13: 1152–1159, 1995

    Google Scholar 

  24. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte O, Klaassen U, Namer M, Bonneterre J, Fumoleau P, Winograd B: Randomized trial of two doses of paclitaxel in metastatic breast cancer. J Clin Oncol 14: 1858–1867, 1996

    Google Scholar 

  25. Gianni L, Capri G, Munzone E, Straneo M: Paclitaxel (taxol) efficacy in patients with advanced breast cancer resistant to anthracyclines. Semin Oncol 21(5 Suppl 8): 29–33, 1994

    Google Scholar 

  26. Vermorken JB, Ten Bokkel Huinink WW, Mandjes IA, Postma TJ, Huizing MT, Heimans JJ, Beijnen JH, Bierhorst F, Winograd B, Pinedo HM: High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial. Semin Oncol 22(4 Suppl 8): 16–22, 1995

    Google Scholar 

  27. Degardin M, Bonneterre J, Hecquet B, Pion JM, Adenis A, Horner D, Demaille A: Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer. Ann Oncol 5: 423–426, 1994

    Google Scholar 

  28. Jones S, Winer E, Vogel C, Laufman L, Hutchins L, O'Rourke M, Lembersky B, Budman D, Bigley J, Hohneker J: Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13: 2567–2574, 1995

    Google Scholar 

  29. Lokich JJ, Moore CL, Anderson NR: Comparison of costs for infusion versus bolus chemotherapy administration: Analysis of five chemotherapy regimens in three common tumors. Part one. Model projections for cost based on charges. Cancer 78: 294–299, 1996

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Department, Hospital Universitario San Carlos, Madrid, Spain

    Yago Nieto, Miguel Martín, José Luis Alonso, Antonio Casado, Francisco Ayala, José Antonio López-Martín, Alvaro Rodríguez-Lescure & Eduardo Díaz-Rubio

Authors
  1. Yago Nieto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Miguel Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Luis Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Antonio Casado
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francisco Ayala
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. José Antonio López-Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alvaro Rodríguez-Lescure
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Eduardo Díaz-Rubio
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nieto, Y., Martín, M., Alonso, J.L. et al. Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin. Breast Cancer Res Treat 50, 167–174 (1998). https://doi.org/10.1023/A:1006062018355

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006062018355

Search

Navigation